‘Ozempic Feet’: Understanding the Latest GLP-1 Side Effect

The global surge in the popularity of GLP-1 receptor agonists—a class of drugs that includes Ozempic, Wegovy, and Mounjaro—has transformed the landscape of weight management and diabetes care. While these medications have been praised for their ability to regulate blood sugar and aid in significant weight reduction, a new, unexpected concern is emerging from patient reports and medical clinics: ‘Ozempic feet.’

While not an official medical diagnosis, the term ‘Ozempic feet’ is being used by healthcare providers to describe a specific phenomenon: patients reporting new, persistent foot pain or a feeling of discomfort, often described as a loss of cushioning or ‘fat pads’ in the soles of their feet after rapid weight loss.

Medical experts suggest that the underlying issue is not the medication itself, but rather the speed at which users are losing weight. Fat pads in the feet play a crucial role in providing cushioning during walking, running, and standing. These pads act as natural shock absorbers, protecting the bones and joints from the impact of daily movement. When weight loss occurs rapidly, the body does not always burn fat proportionately. In some cases, the body may shed subcutaneous fat—the fat stored just under the skin—from the soles of the feet, leaving the bones more exposed to pressure and friction.

This loss of padding can lead to a condition known as metatarsalgia, which causes pain and inflammation in the ball of the foot. Patients may feel as though they are walking directly on the bones, leading to soreness after even short periods of activity. For those who were previously carrying significant extra weight, the feet may have adapted to bear that load. When the weight is removed quickly, the body's structure, which had grown accustomed to the extra mass, is suddenly unsupported.

Physicians emphasize that this side effect is a common consequence of rapid weight loss through any method, including bariatric surgery or extreme dieting, rather than something specific to the chemical composition of GLP-1 drugs. However, because these medications facilitate such quick and significant weight loss, the phenomenon is becoming more visible to the medical community.

Doctors are advising patients who experience this discomfort to focus on supportive footwear. Orthotic inserts, cushioned insoles, and shoes with thick, shock-absorbing soles are often recommended to replace the lost natural padding. In some cases, podiatrists may suggest physical therapy or specific foot exercises to strengthen the muscles surrounding the joints of the foot.

Beyond foot health, the emergence of these side effects serves as a broader reminder of the importance of losing weight in a sustainable and controlled manner. Health organizations generally recommend a gradual approach to weight loss—typically one to two pounds per week—to allow the body to adjust to changes in mass, skin elasticity, and structural support. Rapid weight loss can also lead to other issues, such as gallstones, muscle loss, and nutritional deficiencies, if not closely monitored by medical professionals.

As the use of GLP-1 medications continues to grow worldwide, healthcare providers are encouraging patients to be proactive about reporting any new aches or pains. While the benefits of managing diabetes or obesity can be life-changing, the journey should ideally be managed with professional guidance to mitigate potential side effects, including those involving the musculoskeletal system.

For most, ‘Ozempic feet’ is a manageable condition. By prioritizing proper footwear and adjusting activity levels during the phase of most rapid weight loss, many patients find that their discomfort resolves as their body stabilizes. However, persistent pain should never be ignored, as it could indicate more complex issues such as stress fractures or nerve-related conditions that require clinical intervention.

Consult a healthcare professional.